Published in
Impact Journals, Oncotarget, 12(3), p. 1505-1521, 2012
Links
- Impact Journals
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [thescholarship.ecu.edu] | PDF
Tools
Advances in Targeting Signal Transduction Pathways
,
Stephen L. Abrams,
Richard A. Franklin,
Lucio Cocco,
Camilla Evangelisti,
Francesca Chiarini,
Alberto M. Martelli,
Massimo Libra,
Saverio Candido,
Giovanni Ligresti,
Grazia Malaponte
and other authors.
Full text: Download
Abstract
Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.